H. Kuwano
Cancer Research · 2004–2006
A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from H. Kuwano's perspective
Ordered by how strongly the researchers H. Kuwano trusts endorse each paper. Same corpus, a different order for every researcher.
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
- A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (Clinical Cancer Research)
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (PLoS Medicine)
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
- Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (Journal of the American Medical Association (JAMA))
- Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (Clinical Cancer Research)
- Hallmarks of cancer: the next generation. (Cell)
- Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors (Clinical Cancer Research)